Human Vaccines Market Analysis

Human Vaccines Market Overview

The Middle East and Africa human vaccines market size was valued at USD 0.6 Billion in 2022. The Human Vaccines market industry is projected to grow from USD 0.63 Billion in 2023 to USD 1.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period (2023 - 2032). The high prevalence of chronic conditions such as flu and bacterial infectious diseases, the presence of pipeline products and regulation processes and the document formation of the manufacturing companies are the key market drivers enhancing the market growth.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

The presence of pipeline items and the high frequency of chronic conditions, including transmissible flu and bacterial illnesses, drove market demand throughout the projection period. By assisting the body's immune system in fortifying defenses against harmful microorganisms, vaccines are a product that can lower the risk of contracting a disease. Numerous vaccines have been developed for deadly diseases, sparing up to 2-3 million deaths annually from illnesses including tetanus, pertussis, measles, diphtheria, and influenza. The main driver of the region's travel vaccines market growth is the ongoing need for life-saving immunizations. This indicates that introducing novel products stimulates the vaccine market to grow. Vendors can extend their consumer bases in emerging markets by utilizing the latest features and technology. This factor probably drives the market for MEA travel vaccinations. During the forecast period, the MEA travel vaccines industry is anticipated to expand at a solid CAGR.

To provide immunity against contagious diseases, vaccines are crucial. Many researchers and vaccine-producing businesses were motivated by the success stories of the vaccines that eliminated polio and smallpox. In recent years, vaccinations have contributed to controlling and preventing COVID-19. Additionally, factors like the expanding population, MEA travel-related underlying bacterial and viral alterations, and the emergence of new dangers that need immediate remedies are likely to increase the demand for vaccinations and are anticipated to flourish the market growth over the forecast year. Launching a new and innovative vaccination wins over patients' trust and offers the market a fresh outlook, which can help the vaccine market grow. Additionally, introducing new vaccines shows that market participants are actively involved in the growth of vaccines.

Human Vaccines Market Trends

• Strong Supply Backed Up by Robust R&D is driving the market growth

Market CAGR for human vaccines is driven by immunization policies to eradicate endemic diseases and the supply of products enhanced, which is one of the significant drivers for market growth. Government foundations, hospitals and pharmaceutical companies strongly focus on regular immunization and delivering cost-effective immunization to people. Government surveillance in all countries has become active to ensure that every person is vaccinated at a minimum or no cost. The growing demand for shots, including diphtheria tetanus pertussis and others, is one of the major factors for the market growth. Moreover, government funding and firm investments are boosting the R&D sector for launching novel products.

Additionally, technological advancements in vaccine administration will drive market growth over the forecast period. Modern vaccination technologies are primarily motivated by the desire to hasten response times to new threats and make vaccines readily available for rapid deployment. The development of vaccines against challenging targets and the improvement of delivery technologies for maximal potency is also at the center of innovation in the vaccines sector. The creation of synthetic vaccine candidates, genetic analyses of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery methods are a few examples of vaccine delivery technology breakthroughs.

Furthermore, key players' strategic activities like partnerships, acquisitions, and mergers are expected to increase product availability, which is likely to drive market growth over the forecast period. For instance, In April 2022, Dante Labs, a genomics and precision medicine company, was selected as the genetic testing delivers for Abu Dhabi Stem Cells Center, the Abu Dhabi-based professional healthcare center concentrated on cell therapy and regenerative therapy. Hence, regarding the high prevalence of cancer cases and the major players' improved strategic activities, the studied market is expected to drive the human vaccines market revenue.

In addition, recent advances in vaccine technology are now delivering an opportunity to target new diseases. A wide array of new vaccination technologies have been developed, ranging from targeted attenuation techniques of live pathogens to the delivery of biologically engineered protein and peptide antigens and viral vector and nucleic-acid-based antigens. Several of these technologies have yielded highly promising results. Furthermore, an increase in childbirths associated with a high risk of infection due to poor infant immunity, high risk of meningitis, measles, rotavirus, and pneumococcal disease, and growth in awareness toward immunization are some of the factors that provide lucrative opportunities for vaccines across the emerging markets.

Human Vaccines Market Segment Insights

Human Vaccines Technology Insights

The Middle East and Africa human vaccines market segmentation, based on technology, includes attenuated, inactivated, toxoid, conjugate & subunit, and recombinant DNA. The inactivated segment dominated the market, accounting for 35% of market revenue (0.22 Billion). In developing economies, category growth is driven by the surge in demand for influenza and hepatitis A & B. However, conjugate & subunit is the fastest-growing category owing to the availability of various delivery systems options.

Human Vaccines Route of Administration Insights

The Middle East and Africa human vaccines market segmentation, based on the route of administration, includes oral, injectable, and other. The oral category generated the most income (70.4%) owing to challenges faced in developing countries. However, injectable is the fastest-growing category owing to the growing prevalence of bacterial and viral diseases.

Human Vaccines Type Insights

The Middle East and Africa human vaccines market segmentation, based on type, includes prophylactic and therapeutic. The therapeutic segment dominated the market, accounting for major market revenue due to increased R&D efforts by pharmaceutical companies to improve various preventative vaccination. However, prophylactic is the fastest-growing category due to increased mergers and alliances.

Human Vaccines Disease Indication Insights

The Middle East and Africa human vaccines market segmentation, based on disease indication, includes pneumococcal, influenza, hepatitis, rotavirus, DTP, polio, and others. The hepatitis category generated the most income owing to the upcoming launch of hepatitis vaccines and increasing HPV sales. However, pneumococcal is the fastest-growing category due to higher pneumococcal sales in this region.

Human Vaccines End User Insights

The Middle East and Africa human vaccines market segmentation, based on End User, includes children and adults. The children segment dominated the market, accounting for major market revenue. In developing economies, category growth is driven by the growing birth cohort and increasing pediatric vaccination doses. However, adults are the fastest-growing category owing to a rise in research & development and a strong pipeline.

Human Vaccines Composition Insights

The Middle East and Africa human vaccines market segmentation, based on composition, includes mono vaccine and combination vaccine. The combination vaccine category generated the most income owing to a rise in the number of patients with cancer, influenza, infectious diseases, and respiratory illnesses. However, the mono vaccine is the fastest-growing category owing to the increased investments by operating players to produce advanced and effective vaccines.

Figure 1 Middle East and Africa Human Vaccines Market, by Composition, 2022 & 2032 (USD Billion)

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

News

By intensifying its partnerships with pharmaceutical behemoths like Sinopharm, Moderna, and Pfizer, the UAE has since 2021 developed into a regional center in the worldwide vaccine manufacturing and distribution chain. Another advantage of the UAE's involvement in global vaccination politics will be its ability to bridge the gap between the West, China, and Russia. The UAE's close relations with Asia's developing nations, including India, China, and Japan, will encourage collaboration in manufacturing and distributing vaccines. The UAE will oversee offering vaccines and medical assistance for developing nations in Africa, Asia, and the Middle East in fulfillment of its function as a local vaccine hub at a time when "every nation for itself" politics and "self-help" doctrines rule the foreign policies of several great global powers.

Human Vaccines Countries Insights

By countries, the study provides market insights into GCC, South Africa and the Rest of MEA. The GCC human vaccines market will dominate due to several factors, including vaccination awareness, strong manufacturers, and secure government policy regarding health welfare.

Figure 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET SHARE BY COUNTRIES 2022 (USD Billion)

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

South Africa's human vaccines market accounts for the second-largest market share to the increased patient population and awareness regarding rare genetic diseases. Moreover, major players are operating in this country, and an increasing need for mRNA vaccines and therapeutics drives market growth.

The Rest of the MEA human vaccines market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to expanding awareness of a healthy lifestyle and rising per capita disposable income. The widespread use of human vaccines and therapeutics to treat various chronic diseases is moving the market for human vaccines forward.

Human Vaccines Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the human vaccines market grow even more. Market participants are also undertaking several strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the human vaccines industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Middle East and Africa human vaccines industry to benefit clients and increase the market sector. The Human Vaccines industry has offered some of the most significant medical advantages in recent years. Major players in the human vaccines market, including Valneva SE, Takeda Pharmaceutical Company Limited, Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Services, LLC, and others, are attempting to increase market demand by investing in research and development operations.

Abbott Laboratories discovers, develops, manufactures and markets a diversified range of healthcare products, such as diagnostic systems and tests, branded generic pharmaceuticals, and pediatric and adult nutritional products. The firm also offers several medical devices, including electrophysiology, heart failure, rhythm management, vascular and structural heart devices, and neuromodulation devices. The firm also delivers dietary supplements and minerals, and nutrition products. It has research and development facilities in the US, Colombia, China, India, Singapore, Spain, and the UK; and operates manufacturing facilities worldwide. In February 2020, Abbott launched a new quadrivalent and sub-unit vaccine. The vaccine launched can protect against four viral influenza strains. The product launch boosted the company's product portfolio and allowed it to generate more revenue.

Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat cardiovascular, metabolic and pain conditions, women's health, cancer, inflammation, immune disorders, and rare diseases. It also delivers sterile injectable pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars, and contract manufacturing services. Pfizer sells its products through wholesalers, hospitals, retailers, individual provider offices, clinics, government agencies and pharmacies. In February 2022, Pfizer renewed its partnerships with United Arab Emirates-based cancer patient societies Friends of Cancer Patients (FOCP) and Emirates Oncology Society to mark World Cancer Day. The pharmaceutical company has reinforced its commitment to advance oncology care, encourage early detection, and support cancer treatment in the country.

Key Companies in the Human Vaccines market include

• GlaxoSmithKline Plc.


• Merck & Co. Inc.


• Pfizer Inc.


• Sanofi Pasteur Inc.


• AstraZeneca Plc.


• Bharat Biotech


• Shenzhen Kangtai Biological Products


• Valeant Pharmaceuticals


• Emergent Biosolutions Inc.


• Astellas Pharma Inc.


• Panacea Biotec

Human Vaccines Industry Developments

April 2022:Dante Labs reported that the company was selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines. Dante and the ADSCC will partner on the launch of an R&D program focusing on personalized treatments for oncology patients and, eventually, the development of cancer vaccines.

Human Vaccines Market Segmentation

Human Vaccines Technology Outlook

• Attenuated


• Inactivated


• Toxoid


• Conjugate & Subunit


• Recombinant DNA

Human Vaccines Route of Administration Outlook

• Oral


• Injectable


• Other

Human Vaccines Type Outlook

• Prophylactic


• Therapeutic

Human Vaccines Disease Indication Outlook

• Pneumococcal


• Influenza


• Hepatitis


• Rotavirus


• DTP


• Polio


• Others

Human Vaccines End User Outlook

• Children


• Adults

Human Vaccines Composition Outlook

• Mono Vaccine


• Combination Vaccine

Human Vaccines Countries Outlook

• Middle East


• Africa